The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial
Jonathan Kingslake, Michael Browning(Oxford Health NHS Foundation Trust), Dick J. Veltman(Vrije Universiteit Amsterdam), Anne G. Lever(Amsterdam University Medical Centers), Guy M. Goodwin(Warneford Hospital), Philip Gorwood(Inserm), Boliang Guo(University of Nottingham), Michael Stäblein(Goethe University Frankfurt), Susan Brown(University of Nottingham), Jürgen Deckert(University of Würzburg), Víctor Pérez(Centre National de la Recherche Scientifique), Andreas Reif(University of Würzburg), Richard Morriss(University of Nottingham), Gerard R. Dawson(HR Wallingford), Judit Simon(Medical University of Vienna), Anneke van Schaik(Amsterdam Public Health), Géraldine Voegeli(Université Paris Cité), Colin T. Dourish(University of Oxford), Rebecca Dias, Catherine J. Harmer(Warneford Hospital), Henricus G. Ruhé(Radboud University Nijmegen), Andreas Menke(Klinik und Poliklinik für Psychiatrie und Psychotherapie)
Cited by 43
Related Papers
Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis
|The Lancet|2018|3.5k
How mental health care should change as a consequence of the COVID-19 pandemic
|The Lancet Psychiatry|2020|1.9k
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
|Nature Reviews Drug Discovery|2012|1.3k
The consequences of the COVID-19 pandemic on mental health and implications for clinical practice
|European Psychiatry|2020|1.2k
Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group
|Molecular Psychiatry|2015|1.2k